<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01485198</url>
  </required_header>
  <id_info>
    <org_study_id>HE11-022</org_study_id>
    <nct_id>NCT01485198</nct_id>
  </id_info>
  <brief_title>Autologous Stem Cells in Osteoarthritis</brief_title>
  <official_title>Clinical Effects of Autologous Bone Marrow Mononuclear Cell Infusion in Knee Osteoarthritis.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital Universitario Dr. Jose E. Gonzalez</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospital Universitario Dr. Jose E. Gonzalez</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients with osteoarthritis, a degenerative joint disease, that meet inclusion criteria will
      be allocated into two groups:

        -  The control group will receive Acetaminophen 750mg orally every 8 hours

        -  The experimental group will receive Autologous Hematopoietic Stem Cells from bone marrow
           (BMASC)

      Signed informed consent is required, as well as answering a questionnaire.

      Patients in experimental group will receive subcutaneous G-CSF (10ug/kg/day) for 3
      consecutive days and, on the 4th day a bone marrow harvest under general sedation will be
      performed from posterior iliac crests. The patient will remain in the recovery room while the
      cells are processed at the Hematology Service Laboratory. Finally, BMASC will be infused to
      the joint under local anesthesia.

      The procedure is ambulatory.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2011</start_date>
  <completion_date type="Actual">May 2014</completion_date>
  <primary_completion_date type="Actual">August 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Define safety of BM extraction and stem cell joint infusion.</measure>
    <time_frame>1 week</time_frame>
    <description>Measure possible complications of procedure (e.g. pain, bleeding, infection) and range of motion through clinical examination.
Apply a questionnaire consisting of validated Womac® Scale, KSS® (Knee Society Rating System), SF-36® (Health Survey Update), and VAS (Visual Analog Scale) to correlate changes at first week to the baseline questionnaire.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Efficacy of BMSC joint infusion at 4 weeks</measure>
    <time_frame>4 weeks</time_frame>
    <description>Measure possible complications of procedure (e.g. pain, bleeding, infection) and range of motion through clinical examination.
Apply a questionnaire consisting of validated Womac® Scale, KSS® (Knee Society Rating System), SF-36® (Health Survey Update), and VAS (Visual Analog Scale) to correlate changes with first week and baseline questionnaires.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy and final outcome of BMSC joint infusion at 6 months.</measure>
    <time_frame>24 weeks</time_frame>
    <description>Measure possible complications of procedure (e.g. pain, bleeding, infection) and range of motion through clinical examination.
Apply a questionnaire consisting of validated Womac® Scale, KSS® (Knee Society Rating System), SF-36® (Health Survey Update), and VAS (Visual Analog Scale) to correlate changes with 4 week, first week and baseline questionnaires.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">61</enrollment>
  <condition>Osteoarthritis, Knee</condition>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients treated with Acetaminophen</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Experimental</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients who underwent a BMASC extraction and joint infusion</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Bone Marrow Autologous Stem Cells Infusion</intervention_name>
    <description>Extraction and knee infusion of Bone Marrow Autologous Stem Cells</description>
    <arm_group_label>Experimental</arm_group_label>
    <other_name>Knee treatment with stem cells</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Acetaminophen</intervention_name>
    <description>Acetaminophen (750mg orally TID) administration</description>
    <arm_group_label>Control</arm_group_label>
    <other_name>Knee treatment with NSAIDs</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with knee osteoarthritis grade II or III of the Kellgren-Lawrence
             radiographic scale

          -  Age &gt; 30 years

        Exclusion Criteria:

          -  Neurodegenerative, autoimmune, genetic or psychiatric diseases

          -  Active infection

          -  Recent joint infection

          -  Knee surgery history

          -  Knee joint fracture history
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Domingo Garay Mendoza, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Universitario Dr. Jose E. Gonzalez</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Consuelo Mancias Guerra, MD</last_name>
    <role>Study Director</role>
    <affiliation>Hospital Universitario Dr. Jose E. Gonzalez</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Laura Villarreal Martínez, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Hospital Universitario Dr. Jose E. Gonzalez</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hematology Service</name>
      <address>
        <city>Monerrey</city>
        <state>Nuevo Leon</state>
        <zip>64460</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Traumatology Service</name>
      <address>
        <city>Monterrey</city>
        <state>Nuevo Leon</state>
        <zip>64460</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Mexico</country>
  </location_countries>
  <link>
    <url>http://www.ortopedia.org/</url>
    <description>Traumatology Service Web Site</description>
  </link>
  <results_reference>
    <citation>Davatchi F, Abdollahi BS, Mohyeddin M, Shahram F, Nikbin B. Mesenchymal stem cell therapy for knee osteoarthritis. Preliminary report of four patients. Int J Rheum Dis. 2011 May;14(2):211-5. doi: 10.1111/j.1756-185X.2011.01599.x. Epub 2011 Mar 4.</citation>
    <PMID>21518322</PMID>
  </results_reference>
  <results_reference>
    <citation>de Girolamo L, Bertolini G, Cervellin M, Sozzi G, Volpi P. Treatment of chondral defects of the knee with one step matrix-assisted technique enhanced by autologous concentrated bone marrow: in vitro characterisation of mesenchymal stem cells from iliac crest and subchondral bone. Injury. 2010 Nov;41(11):1172-7. doi: 10.1016/j.injury.2010.09.027. Epub 2010 Oct 8.</citation>
    <PMID>20934693</PMID>
  </results_reference>
  <results_reference>
    <citation>Chen FM, Wu LA, Zhang M, Zhang R, Sun HH. Homing of endogenous stem/progenitor cells for in situ tissue regeneration: Promises, strategies, and translational perspectives. Biomaterials. 2011 Apr;32(12):3189-209. doi: 10.1016/j.biomaterials.2010.12.032. Review.</citation>
    <PMID>21300401</PMID>
  </results_reference>
  <verification_date>February 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 26, 2011</study_first_submitted>
  <study_first_submitted_qc>December 2, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 5, 2011</study_first_posted>
  <last_update_submitted>February 29, 2016</last_update_submitted>
  <last_update_submitted_qc>February 29, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 1, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hospital Universitario Dr. Jose E. Gonzalez</investigator_affiliation>
    <investigator_full_name>Consuelo Mancias Guerra</investigator_full_name>
    <investigator_title>Head of Hematology Service</investigator_title>
  </responsible_party>
  <keyword>osteoarthritis</keyword>
  <keyword>knee</keyword>
  <keyword>stem cell therapy</keyword>
  <keyword>bone marrow</keyword>
  <keyword>G-CSF</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis</mesh_term>
    <mesh_term>Osteoarthritis, Knee</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acetaminophen</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

